CA2877299C - Methods of treating or preventing periodontitis and diseases associated with periodontitis - Google Patents
Methods of treating or preventing periodontitis and diseases associated with periodontitis Download PDFInfo
- Publication number
- CA2877299C CA2877299C CA2877299A CA2877299A CA2877299C CA 2877299 C CA2877299 C CA 2877299C CA 2877299 A CA2877299 A CA 2877299A CA 2877299 A CA2877299 A CA 2877299A CA 2877299 C CA2877299 C CA 2877299C
- Authority
- CA
- Canada
- Prior art keywords
- periodontitis
- pharmaceutical composition
- methods
- compound
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000001245 periodontitis Diseases 0.000 title claims abstract description 57
- 238000000034 method Methods 0.000 title abstract description 44
- 201000010099 disease Diseases 0.000 title abstract description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 22
- 150000001875 compounds Chemical class 0.000 claims abstract description 44
- 230000000694 effects Effects 0.000 claims description 22
- 230000014509 gene expression Effects 0.000 claims description 22
- 230000004913 activation Effects 0.000 claims description 17
- 241000605862 Porphyromonas gingivalis Species 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 208000005888 Periodontal Pocket Diseases 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 1
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 1
- 238000012216 screening Methods 0.000 abstract description 5
- 239000003112 inhibitor Substances 0.000 description 26
- 239000000203 mixture Substances 0.000 description 20
- 206010065687 Bone loss Diseases 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 16
- 102000004127 Cytokines Human genes 0.000 description 14
- 108090000695 Cytokines Proteins 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- RDTRHBCZFDCUPW-KWICJJCGSA-N 2-[(4r,7s,10s,13s,19s,22s,25s,28s,31s,34r)-4-[[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-34-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-[3-(diaminomethylideneamino)propyl]-10,13-bis(1h-imidazol-5-ylmethyl)-19-(1h-indol Chemical compound C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@@H](C(N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)NCC(=O)N[C@@H](CC=2NC=NC=2)C(=O)N1)C(C)C)C(C)C)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)C1=CN=CN1 RDTRHBCZFDCUPW-KWICJJCGSA-N 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 108010027437 compstatin Proteins 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 9
- 210000003731 gingival crevicular fluid Anatomy 0.000 description 9
- 230000002757 inflammatory effect Effects 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 210000000988 bone and bone Anatomy 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 210000004261 periodontium Anatomy 0.000 description 7
- 241000282693 Cercopithecidae Species 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 208000028169 periodontal disease Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000009368 gene silencing by RNA Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 208000002679 Alveolar Bone Loss Diseases 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 108091030071 RNAI Proteins 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- -1 coatings Substances 0.000 description 4
- 230000024203 complement activation Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 101150018425 Cr1l gene Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000008108 Osteoprotegerin Human genes 0.000 description 3
- 108010035042 Osteoprotegerin Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000014128 RANK Ligand Human genes 0.000 description 3
- 108010025832 RANK Ligand Proteins 0.000 description 3
- 239000004074 complement inhibitor Substances 0.000 description 3
- 102000006834 complement receptors Human genes 0.000 description 3
- 108010047295 complement receptors Proteins 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000004195 gingiva Anatomy 0.000 description 3
- 229940100601 interleukin-6 Drugs 0.000 description 3
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 description 2
- 101710098483 C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 description 2
- 108010009575 CD55 Antigens Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 102000050019 Membrane Cofactor Human genes 0.000 description 2
- 101710146216 Membrane cofactor protein Proteins 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000007470 bone biopsy Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000002050 maxilla Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 241001316595 Acris Species 0.000 description 1
- 108010089414 Anaphylatoxins Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 101710159767 C4b-binding protein alpha chain Proteins 0.000 description 1
- 102100037084 C4b-binding protein alpha chain Human genes 0.000 description 1
- 102100022002 CD59 glycoprotein Human genes 0.000 description 1
- 102000003780 Clusterin Human genes 0.000 description 1
- 108090000197 Clusterin Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108010053085 Complement Factor H Proteins 0.000 description 1
- 102000016550 Complement Factor H Human genes 0.000 description 1
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 229940124073 Complement inhibitor Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930184725 Lipoxin Natural products 0.000 description 1
- 108010085169 Lysine carboxypeptidase Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010072574 Periodontal inflammation Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010005642 Properdin Proteins 0.000 description 1
- 102100038567 Properdin Human genes 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 244000107946 Spondias cytherea Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 108010073240 complement C5a-inhibitors Proteins 0.000 description 1
- 201000008560 complement component 3 deficiency Diseases 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 210000004513 dentition Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 201000005562 gingival recession Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000021059 hard food Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 150000002639 lipoxins Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000019656 metallic taste Nutrition 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 210000005088 multinucleated cell Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 230000002177 osteoclastogenic effect Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000002379 periodontal ligament Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000036346 tooth eruption Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/18—Dental and oral disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261662022P | 2012-06-20 | 2012-06-20 | |
| US61/662,022 | 2012-06-20 | ||
| US13/801,096 US9579360B2 (en) | 2012-06-20 | 2013-03-13 | Methods of treating or preventing periodontitis and diseases associated with periodontitis |
| US13/801,096 | 2013-03-13 | ||
| PCT/US2013/046599 WO2013192319A1 (en) | 2012-06-20 | 2013-06-19 | Methods of treating or preventing periodontitis and diseases associated with periodontitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2877299A1 CA2877299A1 (en) | 2013-12-27 |
| CA2877299C true CA2877299C (en) | 2022-07-12 |
Family
ID=49769337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2877299A Active CA2877299C (en) | 2012-06-20 | 2013-06-19 | Methods of treating or preventing periodontitis and diseases associated with periodontitis |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9579360B2 (enEXAMPLES) |
| EP (1) | EP2863949B1 (enEXAMPLES) |
| JP (1) | JP6363595B2 (enEXAMPLES) |
| CN (1) | CN104640567A (enEXAMPLES) |
| AU (1) | AU2013277217B2 (enEXAMPLES) |
| CA (1) | CA2877299C (enEXAMPLES) |
| IN (1) | IN2015DN00438A (enEXAMPLES) |
| WO (1) | WO2013192319A1 (enEXAMPLES) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9630992B2 (en) * | 2011-09-07 | 2017-04-25 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with improved pharmacokinetic properties |
| US9579360B2 (en) * | 2012-06-20 | 2017-02-28 | The Trustees Of The University Of Pennsylvania | Methods of treating or preventing periodontitis and diseases associated with periodontitis |
| CN106413707A (zh) | 2014-02-25 | 2017-02-15 | 艾其林医药公司 | 用于治疗补体介导的疾病的酰胺化合物 |
| HRP20211561T8 (hr) | 2014-06-12 | 2022-03-04 | Ra Pharmaceuticals, Inc. | Modulacija aktivnosti komplementa |
| PL3250230T3 (pl) | 2015-01-28 | 2022-02-14 | Ra Pharmaceuticals, Inc. | Modulatory aktywności dopełniacza |
| EP3340983B1 (en) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| LT3685847T (lt) | 2015-12-16 | 2023-03-27 | Ra Pharmaceuticals, Inc. | Komplemento aktyvumo moduliatoriai |
| CA3045114A1 (en) | 2016-12-07 | 2018-06-14 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| CA3053818A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
| WO2019028284A1 (en) | 2017-08-02 | 2019-02-07 | Achillion Pharmaceuticals, Inc. | THERAPEUTIC REGIMES FOR THE TREATMENT OF NOCTURNAL PAROXYSTIC HEMOGLOBINURIA |
| CA3084043A1 (en) | 2017-12-04 | 2019-06-13 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| KR20240167712A (ko) * | 2017-12-15 | 2024-11-27 | 아펠리스 파마슈티컬스 인코포레이티드 | 투여 요법 및 관련 조성물 및 방법 |
| PL3645550T3 (pl) | 2018-04-06 | 2022-04-04 | The Trustees Of The University Of Pennsylvania | Analogi kompstatyny o zwiększonej rozpuszczalności i ulepszonych właściwościach farmakokinetycznych |
| CN112839945A (zh) | 2018-09-06 | 2021-05-25 | 艾其林医药公司 | 补体因子d抑制剂的形态形式 |
| US11814391B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| WO2020069024A1 (en) | 2018-09-25 | 2020-04-02 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
| JP7471300B2 (ja) | 2018-12-17 | 2024-04-19 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 補体介在性疾患を治療するための的を絞った投与 |
| US20220160820A1 (en) | 2019-03-08 | 2022-05-26 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| BR112021018456A2 (pt) | 2019-03-22 | 2021-11-23 | Achillion Pharmaceuticals Inc | Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento |
| CA3134614A1 (en) | 2019-03-29 | 2020-10-08 | Ra Pharmaceuticals, Inc. | Complement modulators and related methods |
| CA3137895A1 (en) | 2019-04-24 | 2020-10-29 | Ra Pharmaceuticals, Inc. | Compositions and methods for modulating complement activity |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5270365A (en) | 1991-12-17 | 1993-12-14 | Merck & Co., Inc. | Prevention and treatment of periodontal disease with alendronate |
| US5627264A (en) * | 1994-03-03 | 1997-05-06 | Alexion Pharmaceuticals, Inc. | Chimeric complement inhibitor proteins |
| JP2001294536A (ja) * | 2000-04-12 | 2001-10-23 | Sunstar Inc | 歯周病予防・治療剤 |
| US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| HRP20141053T1 (hr) * | 2005-05-10 | 2014-12-19 | Intermune, Inc. | Derivati piridona za moduliranje stresom aktiviranog sustava protein kinaze |
| AU2008214359B2 (en) * | 2007-02-05 | 2014-01-16 | Apellis Pharmaceuticals, Inc. | Local complement inhibition for treatment of complement-mediated disorders |
| WO2010056399A1 (en) * | 2008-11-17 | 2010-05-20 | Incode Biopharmaceutics, Inc. | Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors |
| DK2424557T3 (en) * | 2009-05-01 | 2018-01-22 | Univ Pennsylvania | MODIFIED COMPSTATIN WITH PEPTID BACKBONE AND C-TERMINAL MODIFICATIONS |
| WO2010132954A1 (en) | 2009-05-21 | 2010-11-25 | Oral Health Australia Pty Ltd | Method of treating periodontal disease by administering antagonists of par-2 |
| ES2519572T3 (es) * | 2009-09-23 | 2014-11-07 | The Regents Of The University Of Colorado, A Body Corporate | Moduladores del receptor de tipo toll y usos de los mismos |
| EP2525814A4 (en) | 2010-01-22 | 2013-09-11 | Univ Louisville Res Found | METHODS OF TREATING OR PREVENTING PERIODONTITIS AND PARODONTIST-RELATED DISEASES |
| US10627412B2 (en) * | 2010-03-17 | 2020-04-21 | Kagoshima University | Periodontal-disease-specific peptide, and treatment and diagnosis of periodontal disease using same |
| AU2012272706B2 (en) * | 2011-06-22 | 2017-07-06 | Apellis Pharmaceuticals, Inc. | Methods of treating chronic disorders with complement inhibitors |
| US9630992B2 (en) * | 2011-09-07 | 2017-04-25 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with improved pharmacokinetic properties |
| US9579360B2 (en) * | 2012-06-20 | 2017-02-28 | The Trustees Of The University Of Pennsylvania | Methods of treating or preventing periodontitis and diseases associated with periodontitis |
-
2013
- 2013-03-13 US US13/801,096 patent/US9579360B2/en active Active
- 2013-06-19 IN IN438DEN2015 patent/IN2015DN00438A/en unknown
- 2013-06-19 CA CA2877299A patent/CA2877299C/en active Active
- 2013-06-19 EP EP13807873.8A patent/EP2863949B1/en active Active
- 2013-06-19 CN CN201380032526.1A patent/CN104640567A/zh active Pending
- 2013-06-19 AU AU2013277217A patent/AU2013277217B2/en active Active
- 2013-06-19 JP JP2015518554A patent/JP6363595B2/ja active Active
- 2013-06-19 WO PCT/US2013/046599 patent/WO2013192319A1/en not_active Ceased
-
2017
- 2017-01-27 US US15/418,441 patent/US10668135B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013277217A1 (en) | 2015-01-22 |
| US20170202935A1 (en) | 2017-07-20 |
| US9579360B2 (en) | 2017-02-28 |
| EP2863949A4 (en) | 2016-03-02 |
| EP2863949A1 (en) | 2015-04-29 |
| CA2877299A1 (en) | 2013-12-27 |
| US20130344082A1 (en) | 2013-12-26 |
| AU2013277217A2 (en) | 2015-01-22 |
| US10668135B2 (en) | 2020-06-02 |
| IN2015DN00438A (enEXAMPLES) | 2015-06-19 |
| CN104640567A (zh) | 2015-05-20 |
| AU2013277217B2 (en) | 2018-03-08 |
| JP2015523999A (ja) | 2015-08-20 |
| WO2013192319A1 (en) | 2013-12-27 |
| EP2863949B1 (en) | 2019-01-23 |
| JP6363595B2 (ja) | 2018-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2877299C (en) | Methods of treating or preventing periodontitis and diseases associated with periodontitis | |
| US20220025028A1 (en) | Methods of Treating or Preventing Periodontitis and Diseases Associated with Periodontitis | |
| Maekawa et al. | Genetic and intervention studies implicating complement C3 as a major target for the treatment of periodontitis | |
| Hajishengallis et al. | Complement-dependent mechanisms and interventions in periodontal disease | |
| de Molon et al. | Long-term evaluation of oral gavage with periodontopathogens or ligature induction of experimental periodontal disease in mice | |
| Yu et al. | An essential role for IL-17 in preventing pathogen-initiated bone destruction: recruitment of neutrophils to inflamed bone requires IL-17 receptor–dependent signals | |
| Kinane | Causation and pathogenesis of periodontal disease | |
| Schenkein et al. | Cytokines and inflammatory factors regulating immunoglobulin production in aggressive periodontitis. | |
| US20140302027A1 (en) | Methods of treating periodontal inflammation and periodontal bone loss | |
| Zhou et al. | Fusobacterium nucleatum exacerbates the progression of pulpitis by regulating the STING‐dependent pathway | |
| Sehra et al. | Scratching the surface: towards understanding the pathogenesis of atopic dermatitis | |
| Tang et al. | Dasatinib and Quercetin Mitigate Age‐Related Alveolar Bone Inflammaging and Neutrophil Infiltration | |
| Ye et al. | Periodontitis aggravates pulmonary fibrosis by Porphyromonas gingivalis-promoted infiltration of neutrophils and Th17 cells | |
| Han et al. | Pasteurella multocidia toxin aggravates ligatured-induced periodontal bone loss and inflammation via NOD-like receptor protein 3 inflammasome | |
| Alshaikh | The Role of KDM3C in Oral and Systemic Inflammation During Aging | |
| Cheat | Role of NLRP3 inflammasome in Porphyromonas gingivalis-induced periodontitis | |
| Hasan et al. | A novel experimental model to investigate fungal involvement shows expression of Dectin‐1 in periapical lesion pathogenesis | |
| Zenobia | Oral Polymicrobial Communities in Health and Disease | |
| Dharmayanti et al. | Sex-Based Differences in Gingival Inflammatory Responses to Porphyromonas gingivalis in Male and Female Rats | |
| Zaidi et al. | mltG gene deletion mitigated virulence potential of Streptococcus mutans: An in‑vitro, ex‑situ andin‑vivo study | |
| Yu et al. | Tolerance Induced by Porphyromonas gingivalis Altered Inflammatory Responses in Mice | |
| Mooney | Characterizing A20 function in periodontal tissue homeostasis | |
| Alshabab | RANKL From Osteocytes Contributes to Periodontal Bone Loss | |
| Model | GINGIVAL CREVICULAR FLUID PROTEINASE 3 LEVELS IN DIFFERENT PERIODONTAL DISEASES | |
| Evans et al. | An essential role for IL-17 in preventing pathogen-initiated bone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180518 |
|
| EEER | Examination request |
Effective date: 20180518 |
|
| EEER | Examination request |
Effective date: 20180518 |